Exelixis, Bristol-Myers Squibb and Ipsen side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Exelixis | Bristol-Myers Squibb | Ipsen |
|---|---|---|---|
| Phase 1 | Exelixis: 2 of its 4 programs at phase 1 | Bristol-Myers Squibb: 17 of its 58 programs at phase 1
and 12 more — sign in to see them all | Ipsen: 1 of its 9 programs at phase 1
|
| Phase 2 | 00% | Bristol-Myers Squibb: 18 of its 58 programs at phase 2
and 13 more — sign in to see them all | Ipsen: 4 of its 9 programs at phase 2
|
| Phase 3 | Exelixis: 1 of its 4 programs at phase 3
| Bristol-Myers Squibb: 16 of its 58 programs at phase 3
and 11 more — sign in to see them all | Ipsen: 4 of its 9 programs at phase 3
|
| Approved, new studies | Exelixis: 1 of its 4 programs at approved, new studies
| Bristol-Myers Squibb: 7 of its 58 programs at approved, new studies
and 2 more — sign in to see them all | 00% |
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis2 readouts · 1 phase 3 | · | Exelixis, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · | · | · | Exelixis, May ’27: 1 program whose next study reaches primary completion
| · | · | · | · | · |
| Bristol-Myers Squibb23 readouts · 8 phase 3 | Bristol-Myers Squibb, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3
| Bristol-Myers Squibb, Dec ’26: 8 programs whose next study reaches primary completion, 1 in phase 3
and 3 more — sign in to see them all | Bristol-Myers Squibb, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Bristol-Myers Squibb, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3
| · | · | Bristol-Myers Squibb, May ’27: 1 program whose next study reaches primary completion
| Bristol-Myers Squibb, Jun ’27: 3 programs whose next study reaches primary completion
| Bristol-Myers Squibb, Jul ’27: 1 program whose next study reaches primary completion
| Bristol-Myers Squibb, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Bristol-Myers Squibb, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Bristol-Myers Squibb, Oct ’27: 1 program whose next study reaches primary completion
|
| Ipsen3 readouts · 2 phase 3 | · | Ipsen, Dec ’26: 2 programs whose next study reaches primary completion, 2 in phase 3
| · | · | · | · | · | · | · | · | · | Ipsen, Oct ’27: 1 program whose next study reaches primary completion
|
Changed in the last 90 days
Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Exelixis
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Bristol-Myers Squibb
New programs 5
- BMS-986548phase 2 · first study · Nov 10 · Carcinoma, Non-Small-Cell Lung
- BMS-986485phase 1 · first study · Oct 14
- BMS-986553phase 1 · first study · Oct 8 · Lupus Nephritis
- RYZ711phase 2 · first study · Oct 1 · Prostatic Neoplasms
- BMS-986527phase 1 · first study · Sep 22 · Carcinoma, Renal Cell
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Ipsen
New programs 1
- IPN60350phase 2 · first study · Nov 11 · Neoplasm Metastasis
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 1
- corabotasephase 2 · Aug 2026 → Aug 2027 (+12 mo) · moved Oct 6 · NCT04821089
Where they overlap
Conditions where at least two of them have programs: 9 in all. A program counts in each condition its studies name most.
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
| Target | Exelixis | Bristol-Myers Squibb | Ipsen |
|---|---|---|---|
| CD274 | Anti-NKG2A/Anti-PD-L1 Bispecific Antibody XB628rule | pumitamig | – |
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
- Programs a company names but has not registered are counted apart (Bristol-Myers Squibb: 9).